Fulcrum Therapeutics Shares Drop After 12-Week Data From Pociredir Phase 1b Cohort
Fulcrum Therapeutics Inc. (NASDAQ: FULC) saw its stock decline about 20% on Tuesday after the company released 12-week results from the 20 mg cohort of its Phase 1b PIONEER trial of pociredir in sickle cell disease. Data from 12 evaluable patients showed a mean absolute fetal hemoglobin gain of 12.2 percentage points and improvements in markers of …